Latest Bain Capital Life Sciences Investors, LLC Stock Portfolio
Bain Capital Life Sciences Investors, LLC Performance:
2024 Q3: 7.9%YTD: 5.12%2023: 20.2%
Performance for 2024 Q3 is 7.9%, and YTD is 5.12%, and 2023 is 20.2%.
About Bain Capital Life Sciences Investors, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Bain Capital Life Sciences Investors, LLC reported an equity portfolio of $961.2 Millions as of 30 Sep, 2024.
The top stock holdings of Bain Capital Life Sciences Investors, LLC are NUVL, NAMS, . The fund has invested 28.7% of it's portfolio in NUVALENT INC and 18.1% of portfolio in NEWAMSTERDAM PHARMA COMPANY.
The fund managers got completely rid off ARCUTIS BIOTHERAPEUTICS INC (ARQT) and ACLARIS THERAPEUTICS INC (ACRS) stocks. They significantly reduced their stock positions in TANGO THERAPEUTICS INC (TNGX). Bain Capital Life Sciences Investors, LLC opened new stock positions in CIDARA THERAPEUTICS INC (CDTX). The fund showed a lot of confidence in some stocks as they added substantially to CABALETTA BIO INC (CABA), XILIO THERAPEUTICS INC (XLO) and MARINUS PHARMACEUTICALS INC (MRNS).
The top stock holdings of Bain Capital Life Sciences Investors, LLC are NUVL, NAMS, . The fund has invested 28.7% of it's portfolio in NUVALENT INC and 18.1% of portfolio in NEWAMSTERDAM PHARMA COMPANY.
The fund managers got completely rid off ARCUTIS BIOTHERAPEUTICS INC (ARQT) and ACLARIS THERAPEUTICS INC (ACRS) stocks. They significantly reduced their stock positions in TANGO THERAPEUTICS INC (TNGX). Bain Capital Life Sciences Investors, LLC opened new stock positions in CIDARA THERAPEUTICS INC (CDTX). The fund showed a lot of confidence in some stocks as they added substantially to CABALETTA BIO INC (CABA), XILIO THERAPEUTICS INC (XLO) and MARINUS PHARMACEUTICALS INC (MRNS).
Bain Capital Life Sciences Investors, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Bain Capital Life Sciences Investors, LLC made a return of 7.9% in the last quarter. In trailing 12 months, it's portfolio return was 28.22%.
New Buys
| Ticker | $ Bought |
|---|---|
| cidara therapeutics inc | 7,558,110 |
New stocks bought by Bain Capital Life Sciences Investors, LLC
Additions
| Ticker | % Inc. |
|---|---|
| cabaletta bio inc | 67.33 |
| xilio therapeutics inc | 20.64 |
| marinus pharmaceuticals inc | 18.77 |
| annexon inc | 0.01 |
| syros pharmaceuticals inc | 0.01 |
Additions to existing portfolio by Bain Capital Life Sciences Investors, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| tango therapeutics inc | -6.25 |
Bain Capital Life Sciences Investors, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| arcutis biotherapeutics inc | -9,585,540 |
| aclaris therapeutics inc | -1,100,000 |
Bain Capital Life Sciences Investors, LLC got rid off the above stocks
Sector Distribution
Bain Capital Life Sciences Investors, LLC has about 74% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 74 |
| Others | 25.8 |
Market Cap. Distribution
Bain Capital Life Sciences Investors, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 44 |
| MID-CAP | 28.7 |
| SMALL-CAP | 19.3 |
| MICRO-CAP | 6.8 |
| NANO-CAP | 1.2 |
Stocks belong to which Index?
About 49.7% of the stocks held by Bain Capital Life Sciences Investors, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 50.3 |
| RUSSELL 2000 | 49.7 |
Bain Capital Life Sciences Investors, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC has 24 stocks in it's portfolio. About 89.4% of the portfolio is in top 10 stocks. SYRS proved to be the most loss making stock for the portfolio. NUVL was the most profitable stock for Bain Capital Life Sciences Investors, LLC last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACRS | aclaris therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ADGI | invivyd inc | 0.19 | 1,799,600 | 1,835,590 | unchanged | 0.00 | ||
| ANNX | annexon inc | 5.20 | 8,449,750 | 50,022,500 | added | 0.01 | ||
| ARQT | arcutis biotherapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVIR | atea pharmaceuticals inc | 0.87 | 2,485,640 | 8,326,890 | unchanged | 0.00 | ||
| CABA | cabaletta bio inc | 1.36 | 2,760,890 | 13,031,400 | added | 67.33 | ||
| CCCC | c4 therapeutics inc | 0.66 | 1,111,910 | 6,337,890 | unchanged | 0.00 | ||
| CDTX | cidara therapeutics inc | 0.79 | 703,080 | 7,558,110 | new | |||
| IPSC | century therapeutics inc | 0.96 | 5,410,360 | 9,251,720 | unchanged | 0.00 | ||
| MRNS | marinus pharmaceuticals inc | 0.49 | 2,693,380 | 4,740,350 | added | 18.77 | ||
| MRSN | mersana therapeutics inc | 1.70 | 8,663,670 | 16,374,300 | unchanged | 0.00 | ||
| NAMS | newamsterdam pharma company | 18.09 | 10,473,900 | 173,867,000 | unchanged | 0.00 | ||
| NAMS | newamsterdam pharma company | 0.07 | 100,000 | 700,000 | unchanged | 0.00 | ||
| NAUT | nautilus biotechnology inc | 0.59 | 2,000,000 | 5,700,000 | unchanged | 0.00 | ||
| NUVL | nuvalent inc | 28.71 | 2,697,270 | 275,930,000 | unchanged | 0.00 | ||
| PHVS | pharvaris n v | 6.36 | 3,303,380 | 61,178,600 | unchanged | 0.00 | ||
| RPID | rapid micro biosystems inc | 0.78 | 8,434,560 | 7,506,760 | unchanged | 0.00 | ||
| SLDB | solid biosciences inc | 2.93 | 4,034,580 | 28,121,000 | unchanged | 0.00 | ||
| SVRA | savara inc | 6.42 | 14,565,500 | 61,757,500 | unchanged | 0.00 | ||
| SYRS | syros pharmaceuticals inc | 0.62 | 2,750,150 | 5,912,820 | added | 0.01 | ||